Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures.

Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC.

Drug Metab Dispos. 2000 Nov;28(11):1270-3.

PMID:
11038151
2.

Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.

Althagafy HS, Graf TN, Sy-Cordero AA, Gufford BT, Paine MF, Wagoner J, Polyak SJ, Croatt MP, Oberlies NH.

Bioorg Med Chem. 2013 Jul 1;21(13):3919-26. doi: 10.1016/j.bmc.2013.04.017. Epub 2013 Apr 16.

3.

The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.

Kawaguchi-Suzuki M, Frye RF, Zhu HJ, Brinda BJ, Chavin KD, Bernstein HJ, Markowitz JS.

Drug Metab Dispos. 2014 Oct;42(10):1611-6. doi: 10.1124/dmd.114.057232. Epub 2014 Jul 15.

4.

Drug-drug interactions of silymarin on the perspective of pharmacokinetics.

Wu JW, Lin LC, Tsai TH.

J Ethnopharmacol. 2009 Jan 21;121(2):185-93. doi: 10.1016/j.jep.2008.10.036. Epub 2008 Nov 8. Review.

PMID:
19041708
5.

The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.

Albassam AA, Frye RF, Markowitz JS.

Chem Biol Interact. 2017 Jun 1;271:24-29. doi: 10.1016/j.cbi.2017.04.025. Epub 2017 Apr 27.

PMID:
28457856
6.

Milk thistle's active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction.

Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, Schellens JH, Meijerman I.

Drug Metab Dispos. 2013 Aug;41(8):1494-504. doi: 10.1124/dmd.113.050971. Epub 2013 May 14.

PMID:
23674609
7.

Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.

Brantley SJ, Oberlies NH, Kroll DJ, Paine MF.

J Pharmacol Exp Ther. 2010 Mar;332(3):1081-7. doi: 10.1124/jpet.109.161927. Epub 2009 Nov 24.

8.

Absorption and metabolism of milk thistle flavanolignans in humans.

Calani L, Brighenti F, Bruni R, Del Rio D.

Phytomedicine. 2012 Dec 15;20(1):40-6. doi: 10.1016/j.phymed.2012.09.004. Epub 2012 Oct 13.

PMID:
23072776
9.

Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.

Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC.

Drug Metab Dispos. 2008 Jan;36(1):65-72. Epub 2007 Oct 3.

PMID:
17913795
10.

A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors.

Brantley SJ, Graf TN, Oberlies NH, Paine MF.

Drug Metab Dispos. 2013 Sep;41(9):1662-70. doi: 10.1124/dmd.113.052563. Epub 2013 Jun 25.

11.

Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review.

Soleimani V, Delghandi PS, Moallem SA, Karimi G.

Phytother Res. 2019 Jun;33(6):1627-1638. doi: 10.1002/ptr.6361. Epub 2019 May 8. Review.

PMID:
31069872
12.

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.

van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H.

Clin Cancer Res. 2005 Nov 1;11(21):7800-6.

13.

Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle.

Dunnick JK, Singh B, Nyska A, Peckham J, Kissling GE, Sanders JM.

Toxicol Pathol. 2011 Feb;39(2):398-409. doi: 10.1177/0192623310394211. Epub 2011 Feb 7.

PMID:
21300790
14.

In vivo anticlastogenic effect of silymarin from milk thistle Silybum marianum L.

Anwar S, Madkor HR, Ahmed N, Wagih ME.

Indian J Pharmacol. 2018 May-Jun;50(3):108-115. doi: 10.4103/ijp.IJP_660_16.

15.

Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.

Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I.

Cancer Treat Rev. 2013 Nov;39(7):773-83. doi: 10.1016/j.ctrv.2012.12.008. Epub 2013 Feb 8. Review.

PMID:
23394826
16.

Recent advances in the analysis of flavonolignans of Silybum marianum.

Csupor D, Csorba A, Hohmann J.

J Pharm Biomed Anal. 2016 Oct 25;130:301-317. doi: 10.1016/j.jpba.2016.05.034. Epub 2016 May 26. Review.

PMID:
27321822
18.

Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity.

Ruan X, Shen C, Meng Q.

Food Chem Toxicol. 2010 May;48(5):1145-51. doi: 10.1016/j.fct.2010.02.001. Epub 2010 Feb 4.

PMID:
20138203
19.

Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases.

Jančová P, Siller M, Anzenbacherová E, Křen V, Anzenbacher P, Simánek V.

Xenobiotica. 2011 Sep;41(9):743-51. doi: 10.3109/00498254.2011.573017. Epub 2011 Apr 27.

PMID:
21524189
20.

Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.

Doehmer J, Weiss G, McGregor GP, Appel K.

Toxicol In Vitro. 2011 Feb;25(1):21-7. doi: 10.1016/j.tiv.2010.09.001. Epub 2010 Sep 7.

PMID:
20828605

Supplemental Content

Support Center